Latest News

Ceapro Inc. Reports Second Quarter 2016 Financial and Operational Results – Ceapro completes another record-setting quarter for the highest quarterly revenues reported in Company’s history – Clinical program with avenanthramides as anti-inflammatory compound initiated

EDMONTON, ALBERTA – August 24, 2016 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and six-month periods ended June 30,

Read more

Ceapro Inc. Closes Final Tranche of a Brokered Private Placement

EDMONTON, ALBERTA – July 14, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed the second and final tranche of its previously

Read more

Ceapro Inc. Closes an Initial Tranche of a Brokered Private Placement

EDMONTON, ALBERTA – July 11, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed the first tranche of its previously announced brokered

Read more

Ceapro Inc. Announces No Material Change

EDMONTON, ALBERTA – July 7, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and active ingredients for healthcare and cosmetic industries, is issuing this press release in response to a recent request by the Investment Industry Regulatory

Read more

Ceapro Inc. Announces Brokered Private Placement

EDMONTON, ALBERTA – June 9, 2016 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has appointed Echelon Wealth Partners Inc. (“Echelon” or the “Agent”)

Read more

Ceapro Inc. Reports 2016 First Quarter Financial Results and Provides Corporate Update – Ceapro posts highest quarterly revenues reported in Company’s history – Expected commencement of clinical program with avenanthramides as anti-inflammatory compound before year end – Pilot clinical study to develop beta glucan as a cholesterol reducer on track to initiate in Q3 2016

EDMONTON, ALBERTA – May 18, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the three-months ended March 31, 2016 and provided

Read more

Ceapro Inc. Presents its PGX Technology at the 15th European Meeting on Supercritical Fluids

EDMONTON, ALBERTA – May 9, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented this morning its PGX Technology at the 15th European

Read more

Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook – Ceapro expects to commence clinical program with avenanthramides as anti-inflammatory compound before year end – Pilot clinical study to develop beta glucan as a cholesterol reducer expected to initiate in the third quarter of 2016

EDMONTON, ALBERTA – April 18, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided a business update for the year ended December 31, 2015 and a

Read more

Ceapro Inc. Reports 2015 Financial Results, Best Financial Year in Company’s History – Ceapro posts highest revenues, profits and cash flows reported in Company’s history for both Q4 2015 and FY 2015

EDMONTON, ALBERTA – April 14, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the twelve-months ended December 31, 2015. The Company’s

Read more

Ceapro Announces Renewal of a Long Term License and Distribution Agreement with Symrise – Symrise is leading global provider of active ingredients for the distribution and commercialization of Ceapro’s high value active ingredients in the cosmetic market.

EDMONTON, ALBERTA, April 6, 2016 – Ceapro Inc. (CZO –V) (“Ceapro” or “the Company”) a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of a new long term agreement with German-based multinational, Symrise AG,

Read more
Page 2 of 1012345...10...Last »